Targeting transgene to the heart and liver with AAV9 by different promoters

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 10, 2015, Pages 1108-1117

  Chen, Bang Dang ^a   He, Chun Hui ^a,b   Chen, Xiao Cui ^a   Pan, Shuo ^b   Liu, Fen ^a   Ma, Xiang ^b   Li, Xiao Mei ^b   Gai, Min Tao ^a   Tao, Jing ^b   Ma, Yi Tong ^a,b   Yang, Yi Ning ^a,b   Gao, Xiao Ming ^a,c  

^a Clinical Medical Research Institute   (China)

^b XINJIANG MEDICAL UNIVERSITY   (China)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

AAV9; CBA promoter; CMV promoter; Heart; Liver; rBac based system

Indexed keywords

ADENOVIRUS VECTOR; BIOLOGICAL MARKER; GREEN FLUORESCENT PROTEIN; ACTIN;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; CYTOMEGALOVIRUS; FLOW CYTOMETRY; GENE DOSAGE; GENE TARGETING; HEART; KIDNEY FUNCTION TEST; LIVER; MALE; MOUSE; NONHUMAN; PROMOTER REGION; STUDY; TRANSGENE; VIRUS GENOME; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE CELL; CHICKEN; CYTOLOGY; DEPENDOPARVOVIRUS; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; LIVER CELL; METABOLISM; PHYSIOLOGY; PROCEDURES; SAFETY; VIRAL TROPISM; VIROLOGY;

ACTINS; ANIMALS; APOPTOSIS; CHICKENS; CYTOMEGALOVIRUS; DEPENDOVIRUS; GENETIC VECTORS; HEPATOCYTES; MALE; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; PROMOTER REGIONS, GENETIC; SAFETY; TRANSDUCTION, GENETIC; TRANSGENES; VIRAL TROPISM;

EID: 84941560012     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12453     Document Type: Article

References (28)

1. Pacak CA, Byrne BJ. AAV vectors for cardiac gene transfer: Experimental tools and clinical opportunities. Mol. Ther. 2011; 19: 1582-90.
2. Skubis-Zegadlo J, Stachurska A, Malecki M. Vectrology of adeno-associated viruses (AAV). Med. Wieku. Rozwoj. 2013; 17: 202-6.
3. Aikawa R, Huggins GS, Snyder RO. Cardiomyocyte-specific gene expression following recombinant adeno-associated viral vector transduction. J. Biol. Chem. 2002; 277: 18979-85.
4. Prasad KM, Xu Y, Yang Z, Toufektsian MC, Berr SS, French BA. Topoisomerase inhibition accelerates gene expression after adeno-associated virus-mediated gene transfer to the mammalian heart. Mol. Ther. 2007; 15: 764-71.
5. Bostick B, Ghosh A, Yue Y, Long C, Duan D. Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther. 2007; 14: 1605-9.
6. Gregorevic P, Blankinship MJ, Allen JM et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 2004; 10: 828-34.
7. Inagaki K, Fuess S, Storm TA et al. Robust systemic transduction with AAV9 vectors in mice: Efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 2006; 14: 45-53.
8. Pacak CA, Mah CS, Thattaliyath BD et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ. Res. 2006; 99: e3-9.
9. Wang Z, Zhu T, Qiao C et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 2005; 23: 321-8.
10. Prasad KM, Xu Y, Yang Z, Acton ST, French BA. Robust cardiomyocyte-specific gene expression following systemic injection of AAV: In vivo gene delivery follows a Poisson distribution. Gene Ther. 2011; 18: 43-52.
11. Pacak CA, Sakai Y, Thattaliyath BD, Mah CS, Byrne BJ. Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice. Genet. Vaccines. Ther. 2008; 6: 13.
12. Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther. 2003; 10: 2105-11.
13. Xu L, Daly T, Gao C et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum. Gene Ther. 2001; 12: 563-73.
14. Gray SJ, Foti SB, Schwartz JW et al. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum. Gene Ther. 2011; 22: 1143-53.
15. Beltran WA, Boye SL, Boye SE et al. rAAV2/5 gene-targeting to rods:Dose-dependent efficiency and complications associated with different promoters. Gene Ther. 2010; 17: 1162-74.
16. Virag T, Cecchini S, Kotin RM. Producing recombinant adeno-associated virus in foster cells: Overcoming production limitations using a baculovirus-insect cell expression strategy. Hum. Gene Ther. 2009; 20: 807-17.
17. Chen H. Intron splicing-mediated expression of AAV Rep and Cap genes and production of AAV vectors in insect cells. Mol. Ther. 2008; 16: 924-30.
18. Chen H. Exploiting the Intron-splicing Mechanism of Insect Cells to Produce Viral Vectors Harboring Toxic Genes for Suicide Gene Therapy. Mol. Ther. Nucleic. Acids. 2012; 1: e57.
19. Yang L, Jiang J, Drouin LM et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc. Natl Acad. Sci. USA 2009; 106: 3946-51.
20. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther. 2002; 13: 1935-43.
21. Snyder BR, Gray SJ, Quach ET et al. Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum. Gene Ther. 2011; 22: 1129-35.
22. Schievenbusch S, Strack I, Scheffler M et al. Combined paracrine and endocrine AAV9 mediated expression of hepatocyte growth factor for the treatment of renal fibrosis. Mol. Ther. 2010; 18: 1302-9.
23. Vandendriessche T, Thorrez L, Acosta-Sanchez A et al. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J. Thromb. Haemost. 2007; 5: 16-24.
24. Salva MZ, Himeda CL, Tai PW et al. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol. Ther. 2007; 15: 320-9.
25. Geisler A, Jungmann A, Kurreck J et al. microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors. Gene Ther. 2011; 18: 199-209.
26. Williams PD, Ranjzad P, Kakar SJ, Kingston PA. Development of viral vectors for use in cardiovascular gene therapy. Viruses 2010; 2: 334-71.
27. Pulicherla N, Shen S, Yadav S et al. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol. Ther. 2011; 19: 1070-8.
28. Qiao C, Yuan Z, Li J et al. Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Ther. 2011; 18: 403-10.